Valneva SE (VALN)
| Market Cap | 1.22B |
| Revenue (ttm) | 395.55M |
| Net Income (ttm) | -83.44M |
| Shares Out | 58.61M |
| EPS (ttm) | -1.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,702 |
| Open | 20.29 |
| Previous Close | 21.42 |
| Day's Range | 20.22 - 21.20 |
| 52-Week Range | 13.71 - 67.84 |
| Beta | 0.93 |
| Analysts | Hold |
| Price Target | 29.89 (+43.5%) |
| Earnings Date | Aug 9, 2022 |
About VALN
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SA... [Read more...]
Financial Performance
In 2021, Valneva SE's revenue was 348.09 million, an increase of 215.52% compared to the previous year's 110.32 million. Losses were -73.43 million, 14.0% more than in 2020.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for VALN stock is "Hold." The 12-month stock price forecast is 29.89, which is an increase of 43.49% from the latest price.
News
Valneva cuts full-year outlook on lower COVID-19 vaccine sales
Vaccine developer Valneva on Thursday cut its full-year revenue outlook to account for lower orders of its COVID-19 vaccine after both the European Union and the UK walked away from supply contracts wor...
Valneva Reports H1 2022 Results and Provides Corporate Updates
Excellent progress on late-stage clinical programs
Pfizer, Valneva begin major test of first possible Lyme vaccine in 20 years
DUNCANSVILLE, Pa. — Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years — in hopes of better fighting the tick-bor...
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
NEW YORK & SAINT-HERBLAIN, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against...
Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva's Inactivated COVID-19 ...
Saint- Herb lain (France ) , August 1 , 2 02 2 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirms the signing of the amendment to its Advance Purchase Agreemen...
European Commission Approves Purchase Agreement Amendment for Valneva's Inactivated COVID-19 Vaccine
European Commission to order 1.25 million doses of Valneva's whole-virus COVID-19 vaccine VLA2001 in 2022
This Biotech Company Is Soaring; Do Not Be Left Out.
Valneva (NASDAQ: VALN) has had a good run this week. It soared 49% at the beginning of trading day Monday and has continued its positive ride.
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001
VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe
Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members
Saint - Herblain ( France), June 24 , 202 2 – Valneva S E (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Management Board w...
Valneva and Pfizer Announce Closing of Equity Investment
Saint- Herblain (France) and New York, June 2 3 , 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced the closing of the equit...
Valneva announces resumption of trading of its ordinary shares on Euronext Paris
Saint - Herblain ( France), June 2 3 , 202 2 – Valneva S E (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces the resumption of trading of its ordinary shares on the regulated m...
Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in E...
Saint Herblain (France ), June 23 , 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...
Valneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar?
Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...
Why Shares Of Valneva SE Are Soaring Today
Valneva SE (NASDAQ: VALN) shares are trading higher after the company and Pfizer announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and L...
This biotech stock is up 100% on Tuesday: here's the catalyst
Pfizer Inc (NYSE: PFE), on Tuesday, doubled down on its partnership with Valneva SE (NASDAQ: VALN) to develop a vaccine for Lyme disease. Shares of the French biotech firm are up nearly 100% this morning.
Why Is Valneva (VALN) Stock Up 85% Today?
Valneva (VALN) stock is rocketing higher on Tuesday following news that Pfizer (PFE) is taking a stake in the vaccine company. The post Why Is Valneva (VALN) Stock Up 85% Today?
The Shopify Split Is Just Days Away, but This Tiny Nasdaq Stock Is Soaring Right Now
Markets looked poised for a rebound on Tuesday.
Pfizer makes equity investment in Valneva as they prepare for Phase 3 trial of Lyme disease vaccine candidate
U.S.-listed shares of Valneva VALN, -13.47% soared 81.9% in premarket trading on Tuesday, the day after Pfizer Inc. PFE, -2.00% announced a $95 million equity investment in Valneva as part of a previous...
Why Are Valneva Shares Rallying Today
Pfizer Inc (NYSE: PFE) will invest €90.5 million ($95 million) for an 8.1% stake in Valneva SE (NASDAQ: VALN), as the companies updated the terms of agreement for Lyme disease vaccine candidate VLA15. P...
Pfizer To Buy 8.1% Stake In French Vaccines Company Valneva
The U.S. pharmaceuticals group will invest €90.5 million ($95.25 million) in Valneva.
Pfizer to buy 8.1% of capital of vaccines company Valneva
French specialty vaccine company Valneva and U.S. healthcare giant Pfizer said they had entered an equity subscription agreement under which Pfizer will invest 90.5 million euros ($95.24 million) in Val...
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme D...
SAINT-HERBLAIN, France & NEW YORK--(BUSINESS WIRE)--Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into a...
Valneva (VALN) Stock Declines 59% in 3 Months: Here's Why
Though Valneva's (VALN) COVID-19 vaccine looks promising, the European Commission's intent to terminate the advance purchase agreement for the vaccine puts the future of the company's COVID-19 vaccine p...
Valneva Announces Settlement Agreement with the UK Government
Saint- Herb lain (France ) , June 15 , 202 2 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a settlement agreement with the Gove...
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe
Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.